You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. TFEB Activator for Alzheimer's Disease Therapy

    SBC: BRILLIANT BIOSCIENCES INC.            Topic: NIA

    One in ten of the persons ageare affected by Alzheimer s diseaseADcausing enormous social and economic burden to the United StatesTo date only five medications have been approved by the FDA for the treatment of the symptoms of ADbut none of them slows or stops the disease progressionWith the recent repeated failures of AD drugs on thesecretase inhibitorsthe need for an effective AD drug became eve ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Imaging Biomarkers of Severe Respiratory Infections in Premature Infants

    SBC: Kitware, Inc.            Topic: NHLBI

    ABSTRACTPrematurity is the largest single cause of death in children under five in the world and lower respiratory tract infectionsLRTIare the top cause of hospitalization and mortality in premature infantsClinical tools to predict and prevent severe LRTI in premature pediatric patients are critically needed to allow early interventions to decrease the high morbidity and mortality in this patient ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Veristride STEP-R: an interactive verbal/auditory gait trainer

    SBC: Veristride, Inc.            Topic: 600

    Veristride IncProject Summary When surveyedof stroke survivors said the ability toget out and aboutis considered between important and essential for a better lifeHoweverthat desire falls short of reality for most stroke survivorsOftenwalking across a neighborhood street or from a car to a home is an insurmountable task with little opportunity for working on improvement in gaitOnce insurance covera ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. KAPS Biotech: A novel biomarker to improve prostate cancer diagnosis

    SBC: Kaps Biotechnology LLC            Topic: 102

    Abstract Prostate cancerCaPis the most common non skin cancer in men and third most common cause of cancer deaths in menBlack men experience a higher burden of incidence and mortality from CaP compared to White menThe Prostate Specific AntigenPSAtesta commonly used biomarker for early diagnosis and management of CaPcannot alone accurately predict the presence of CaPits aggressivenessor the risk of ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Technology for the non-invasive surveilance of post-traumatic compartment syndrome

    SBC: Myolex Inc            Topic: NIAMS

    PROJECT SUMMARYAcute compartment syndromeACSremains one of the most devastating and often overlooked traumatic musculoskeletal disorders in clinical practiceIn this conditionpressure increases in one of the body s spacelimited compartmentsdue most commonly to direct trauma or bone fractureresulting ultimately in an ischemic injury to all of the compartment s contentsincluding muscle and nerveOnce ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Create Ultralong DNA Constructs in One Assembly Step

    SBC: FIREBIRD BIOMOLECULAR SCIENCES LLC            Topic: 400

    Create Ultralong DNA Constructs in One Assembly Step Firebird Biomolecular Sciences LLCSteven ABenner Foundation for Applied Molecular EvolutionShuichi Hoshika AbstractFrost andampSullivan found aglobal market for DNA oligos at $million$million for genesPrivate investment in DNA synthesis companies like TwistGinkgoand DNA Script give collective valuations of several billion dollarsFederal public i ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Mobile Augmented Screening Tool to Increase Adolescent HIV Testing and Linkage to Care

    SBC: Digital Health Empowerment, Inc            Topic: NICHD

    ABSTRACTAdolescents face increased HIV riskinfrequent testinginconsistent linkage to careand a lack of prevention related knowledgeWe propose to address this by completing and evaluating the Mobile Augmented ScreeningMAStool to increase youth HIV testing via a tablet based intervention in clinical settingsand then use text messages to facilitate linkage to care for those who test positiveand deliv ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Genome-wide CRISPR screen to identify pro-myogenic factors for cell therapy of DMD

    SBC: Myos, Inc.            Topic: NIAMS

    Project Abstract Myos Incis developing a cell therapy treatment for patients with Duchenne muscular dystrophyDMDbased on HLA matched donor cells that are pretreated with small molecule cocktails ex vivo to modify genes that will enhance engraftment and fusion and enable muscle regenerationMyos is collaborating with DrLouis KunkelBoston Children s Hospitalto address the issues that led to low effic ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Validation of a salivary miRNA diagnostic test for autism spectrum disorder

    SBC: Quadrant Biosciences Inc.            Topic: 103

    Autism spectrum disorder (ASD) is a continuum of neurodevelopmental characteristics that includes deficits in communication and social interaction, as well as restrictive, repetitive interests and behaviors. ASD is an increasing public health concern, with about 1 in 45 American children diagnosed with ASD in 2014, a 10-fold increase in prevalence over the past 40 years. The effect of ASD on both ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease.

    SBC: ARCHER PHARMACEUTICALS, INC.            Topic: NIA

    Pathological hallmarks of Alzheimerandapos s diseaseADinclude extracellular deposits of Apeptidesintraneuronal aggregates of abnormally phosphorylated tau protein and neuroinflammationMost proposed AD disease modifying therapies have focused on strategies that reduce brain Aamyloid or tau pathological accumulationHoweversuch approaches have been unsuccessful in late stage AD clinical trials and ma ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government